Subtopic Deep Dive
Transcatheter PFO Closure versus Medical Therapy
Research Guide
What is Transcatheter PFO Closure versus Medical Therapy?
Transcatheter PFO closure versus medical therapy compares percutaneous closure devices against antiplatelet or anticoagulant regimens in randomized trials to prevent recurrent stroke in patients with patent foramen ovale (PFO) and cryptogenic stroke.
Randomized trials evaluate periprocedural complications, stroke recurrence rates, and long-term outcomes between PFO closure and medical therapy. Key meta-analyses include Turc et al. (2018) with 178 citations analyzing RCTs like CLOSE, and Saver et al. (2018) with 121 citations reviewing cryptogenic stroke management. Over 10 papers from 2004-2020 address this comparison, with Whitlock et al. (2012) cited 607 times on antithrombotic therapy.
Why It Matters
Trial results guide clinical decisions on PFO closure to reduce stroke recurrence in cryptogenic cases, impacting patient selection via RoPE scores (Kent et al., 2011). Pristipino et al. (2018) provide European guidelines influencing management of thromboembolism. Wolfrum et al. (2013) meta-analysis shows closure reduces stroke risk, informing guidelines and reducing healthcare burden from recurrent events.
Key Research Challenges
Optimal Patient Selection
Identifying cryptogenic stroke patients benefiting from closure over therapy uses RoPE scores but lacks universal criteria (Kent et al., 2011). Pristipino et al. (2018) highlight variability in left circulation thromboembolism risk. Trials like CLOSE show subgroup benefits but generalizability remains unclear (Turc et al., 2018).
Periprocedural Complications
Device-related thrombosis and atrial fibrillation occur post-closure, balanced against stroke prevention (Saver et al., 2018). Whitlock et al. (2012) discuss antithrombotic needs in valvular contexts. Long-term safety data from RCTs is limited.
Long-term Outcome Comparison
RCTs like RESPECT and CLOSE favor closure, but meta-analyses debate anticoagulation superiority in subgroups (Turc et al., 2018). Messé et al. (2016) advise against routine closure outside trials. Sustained efficacy beyond 5 years needs confirmation.
Essential Papers
Antithrombotic and Thrombolytic Therapy for Valvular Disease
Richard Whitlock, Jack Sun, Stephen E. Fremes et al. · 2012 · CHEST Journal · 607 citations
European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
Christian Pristipino, Horst Sievert, Fabrizio D’Ascenzo et al. · 2018 · European Heart Journal · 416 citations
Abstract The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number of medical conditions; however, the subject remains controversial and no official statements have...
Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study
Guillaume Turc, David Calvet, Patrice Guérin et al. · 2018 · Journal of the American Heart Association · 178 citations
Background We conducted a systematic review and meta‐analysis of randomized controlled trials ( RCT s) comparing patent foramen ovale ( PFO ) closure, anticoagulation, and antiplatelet therapy to p...
Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review
Ioanna Koutroulou, Georgios Tsivgoulis, Dimitrios Tsalikakis et al. · 2020 · Frontiers in Neurology · 141 citations
<b>Introduction:</b> Percutaneous closure of patent foramen ovale (PFO) in selected patients with cryptogenic cerebrovascular ischemic events (CEs) decreases the risk of recurrent stroke; however, ...
Practice advisory: Recurrent stroke with patent foramen ovale (update of practice parameter) [RETIRED]
Steven R. Messé, Gary Gronseth, David M. Kent et al. · 2016 · Neurology · 123 citations
Clinicians should not routinely offer percutaneous PFO closure to patients with cryptogenic ischemic stroke outside of a research setting (Level R). In rare circumstances, such as recurrent strokes...
Patent Foramen Ovale Closure Versus Medical Therapy for Cryptogenic Ischemic Stroke
Jeffrey L. Saver, Heinrich P. Mattle, David E. Thaler · 2018 · Stroke · 121 citations
M anaging young and middle-aged patients with cryp- togenic ischemic stroke and a patent foramen ovale (PFO) is a common clinical dilemma for neurologists, cardiologists, and primary care physician...
The Risk of Paradoxical Embolism (RoPE) Study: Developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke
David M. Kent, David E. Thaler, David E Thaler · 2011 · Trials · 107 citations
Reading Guide
Foundational Papers
Start with Whitlock et al. (2012, 607 citations) for antithrombotic context, Kent et al. (2011, 107 citations) for RoPE risk models, and Landzberg et al. (2004, 91 citations) for PFO indications.
Recent Advances
Study Pristipino et al. (2018, 416 citations) for guidelines, Turc et al. (2018, 178 citations) for CLOSE insights, and Koutroulou et al. (2020, 141 citations) for epidemiology.
Core Methods
Core methods include RCTs with percutaneous closure (Amplatzer devices), antiplatelet therapy, RoPE scoring, and meta-analyses of composite stroke endpoints (Turc et al., 2018; Wolfrum et al., 2013).
How PapersFlow Helps You Research Transcatheter PFO Closure versus Medical Therapy
Discover & Search
Research Agent uses searchPapers and citationGraph on 'PFO closure RCTs' to map Turc et al. (2018) connections to CLOSE trial, revealing 416-cited Pristipino et al. (2018) guidelines; exaSearch uncovers RoPE models from Kent et al. (2011); findSimilarPapers expands to Saver et al. (2018).
Analyze & Verify
Analysis Agent applies readPaperContent to extract CLOSE trial outcomes from Turc et al. (2018), then verifyResponse with CoVe chain-of-verification checks meta-analysis stats; runPythonAnalysis computes pooled stroke rates from RCT data using pandas; GRADE grading assesses evidence quality for closure vs. therapy.
Synthesize & Write
Synthesis Agent detects gaps in long-term RoPE data via gap detection and flags contradictions between Messé et al. (2016) and recent trials; Writing Agent uses latexEditText, latexSyncCitations for trial comparison tables, latexCompile for PDF reports, exportMermaid for outcome flowcharts.
Use Cases
"Run meta-analysis on stroke recurrence rates from PFO closure RCTs vs medical therapy."
Research Agent → searchPapers('PFO closure RCTs') → Analysis Agent → runPythonAnalysis(pandas meta-analysis on Turc 2018, Saver 2018 data) → forest plot CSV output with hazard ratios.
"Draft LaTeX review comparing CLOSE and RESPECT trials for PFO closure."
Synthesis Agent → gap detection on Turc 2018 → Writing Agent → latexEditText(draft section) → latexSyncCitations(Whitlock 2012 et al.) → latexCompile → PDF with synced references.
"Find code for RoPE score calculator from PFO papers."
Research Agent → paperExtractUrls(Kent 2011) → paperFindGithubRepo → Code Discovery → githubRepoInspect → Python RoPE implementation for patient risk stratification.
Automated Workflows
Deep Research workflow scans 50+ PFO papers via searchPapers → citationGraph → structured report on closure vs. therapy efficacy with GRADE scores. DeepScan applies 7-step analysis with CoVe checkpoints to verify Wolfrum et al. (2013) meta-analysis risks. Theorizer generates hypotheses on RoPE subgroups from Kent et al. (2011) and Turc et al. (2018).
Frequently Asked Questions
What is transcatheter PFO closure versus medical therapy?
It compares percutaneous device closure of patent foramen ovale against antiplatelet or anticoagulant therapy to prevent recurrent cryptogenic stroke, as reviewed in Saver et al. (2018).
What are key methods in these trials?
Randomized trials like CLOSE use Amplatzer devices versus antiplatelets, with endpoints of stroke recurrence and atrial fibrillation (Turc et al., 2018). Meta-analyses pool hazard ratios (Wolfrum et al., 2013).
What are key papers?
Turc et al. (2018, 178 citations) meta-analyzes CLOSE; Pristipino et al. (2018, 416 citations) gives European PFO guidelines; Kent et al. (2011, 107 citations) develops RoPE scores.
What are open problems?
Optimal anticoagulation post-closure duration and RoPE-based selection in diverse populations remain unresolved (Messé et al., 2016; Pristipino et al., 2018).
Research Cardiovascular and Diving-Related Complications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Transcatheter PFO Closure versus Medical Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers